Loading...
•
Jun 30
Bausch + Lomb Q2 2025 Earnings Report
Bausch + Lomb reported a second-quarter loss despite revenue growth, citing increased operating costs and one-time impacts.
Key Takeaways
In Q2 2025, Bausch + Lomb achieved 5% revenue growth year-over-year to $1.278 billion, but posted a net loss of $62 million due to higher SG&A expenses and product recalls. Adjusted EBITDA fell to $191 million.
Total revenue grew 5% to $1.278 billion, driven by Vision Care and Surgical segments.
Net loss attributable to Bausch + Lomb was $62 million; adjusted net income was $25 million.
Adjusted EPS was $0.07, down from $0.13 in Q2 2024.
Cash flow from operations improved to $35 million, up from $15 million a year earlier.
Bausch + Lomb
Bausch + Lomb
Bausch + Lomb Revenue by Segment
Revenue by Segment
Vision Care Revenue
CapyFin.comSurgical Revenue
CapyFin.comPharmaceuticals Revenue
CapyFin.com Forward Guidance
Bausch + Lomb raised full-year 2025 guidance for revenue and Adjusted EBITDA, citing solid performance and foreign exchange tailwinds.
Positive Outlook
- Full-year 2025 revenue guidance increased to $5.05B–$5.15B
- Constant currency revenue growth now expected at 5–7%
- Adjusted EBITDA excluding IPR&D revised to $860M–$910M
- FX tailwinds increased to $25M for full-year revenue
- Strong Vision Care performance expected to continue
Challenges Ahead
- Net loss driven by SG&A and product recall impact
- Adjusted EPS declined YoY
- Pharmaceutical segment revenue decreased slightly
- Operating loss of $11M in Q2
- Adjusted EBITDA declined by $18M YoY